Chronic Rhinosinusitis Trial, Completed (NCT05672030)

Chronic Rhinosinusitis Trial, Completed NCT05672030 Sponsor: Brigham and Women's Hospital Condition: Chronic Rhinosinusitis

Printed from Voxsanity (voxsanity.com.au) — NCT05672030 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people in total, split evenly across three groups of 10: people with a condition called Aspirin-exacerbated Respiratory Disease (AERD, where aspirin triggers breathing or nasal symptoms), people with nasal polyps who can tolerate aspirin (called aspirin-tolerant chronic rhinosinusitis with nasal polyps), and healthy volunteers. All 30 participants completed the study with no drop-outs. The trial was not testing a treatment — instead, it was focused on whether researchers could successfully collect and analyse biological samples (specifically, certain immune cells called plasma cells) from nasal polyp tissue, and study particular biological signals within those cells and the lining of the nose. The reported data shows that for the primary goal — obtaining a usable genetic activity profile (a "transcriptome," meaning a snapshot of which genes are active) from nasal polyp plasma cells — all 10 participants in each of the three groups provided samples that could be successfully analysed, giving 10 out of 10 in every group. For the two secondary goals, the reported data shows the same result: all 10 participants in each group provided samples from which researchers could measure a specific protein marker on plasma cells (called IL-5Ra), and separately, all 10 in each group provided nasal tissue samples from which a related biological signalling process in the cells lining the nose could be analysed. The reported data therefore shows that the trial achieved its stated aim of obtaining analysable samples from all 30 participants across all three groups and all three measurement goals. The trial was designed to assess whether this type of laboratory analysis was possible, not to test whether any treatment produced a particular health outcome — so no treatment results were reported. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

People who have a condition called AERD (Aspirin-Exacerbated Respiratory Disease, which involves sensitivity to aspirin and related medicines along with nasal polyps and asthma)
People who have chronic rhinosinusitis with nasal polyps (a long-term sinus condition where small growths form inside the nose)
Healthy individuals with no relevant conditions (likely needed for comparison purposes — confirm with trial site)

Who may not be able to join:

People who are currently taking steroid tablets or injections (systemic steroids) at the time of their surgery
People who are currently taking biologic medicines (specialist injectable or infused treatments) for breathing or respiratory conditions at the time of their surgery

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:

Trial: NCT05672030

Sponsor: Brigham and Women's Hospital

Phase: Not Applicable

Status: Completed

Condition: Chronic Rhinosinusitis

More information: https://clinicaltrials.gov/study/NCT05672030

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

People who have a condition called AERD (Aspirin-Exacerbated Respiratory Disease, which involves sensitivity to aspirin and related medicines along with nasal polyps and asthma)
People who have chronic rhinosinusitis with nasal polyps (a long-term sinus condition where small growths form inside the nose)
Healthy individuals with no relevant conditions (likely needed for comparison purposes — confirm with trial site)

Who may not be able to join:

People who are currently taking steroid tablets or injections (systemic steroids) at the time of their surgery
People who are currently taking biologic medicines (specialist injectable or infused treatments) for breathing or respiratory conditions at the time of their surgery

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Completed

Phase

Not Applicable

Sponsor

Brigham and Women's Hospital

Registry

ClinicalTrials.gov

Start date

1 October 2022

Est. completion

1 December 2023

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants With Nasal Polyp Plasma Cell Transcriptome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov